Compare Direxion Daily Semiconductor Bull 3X Shares (SOXL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bull 3X Shares vs TG Therapeutics Inc — how do they compare? Direxion Daily Semiconductor Bull 3X Shares trades at $125.61, while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| SOXL | TGTX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $300.77 | $59.06 |
52-Week Low | $28.60 | $26.94 |
Market Cap | — | $8.53B |
Enterprise Value | — | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXL, the Direxion Daily Semiconductor Bull 3X ETF, gained 5.19% to $123.37, reflecting strong bullish momentum in semiconductor stocks. Technical indicators show a bullish overall signal with moving averages supporting upward momentum, while oscillators remain neutral. Recent news highlights ongoing institutional interest in semiconductor ETFs despite warnings about potential short-term volatility and tariff concerns from US trade policy discussions.
The outlook for SOXL remains tied to semiconductor sector performance, with AI demand providing long-term support. However, investors face significant risks from volatility decay inherent in leveraged ETFs, potential tariff impacts, and crowded trading positioning that could trigger sharp corrections. The ETF's performance is highly correlated with major semiconductor stocks like NVIDIA.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
